President and Chief Executive OfficerDr. Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), and a Member of its Board of Directors. He is regarded as one of the world’s leading experts in tuberculosis and TB drug development. Prior to being appointed President and CEO in 2009, Dr. Spigelman served for five and a half years as the Director of Research & Development at TB Alliance. He was instrumental in forging key organizational partnerships and building the pipeline of TB drug candidates. Notably, Dr. Spigelman was a leader in developing a regimen-based paradigm of TB drug development – a faster and more efficient approach, which is emerging as the gold standard within the TB drug research field.
Dr. Spigelman spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma) prior to joining TB Alliance. As Vice President of R&D at Knoll for eight years, Dr. Spigelman directed clinical development and supervised all R&D activities from basic discovery to regulatory approval and Medical Affairs. He established global R&D processes as part of Knoll's senior R&D management team, oversaw a marked increase in US regulatory filings and approvals, and supervised joint R&D programs with multiple other pharmaceutical companies.
Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine, Neoplastic Diseases and Preventive Medicine. Dr. Spigelman holds board certifications from the American Board of Internal Medicine, the American Board's Subspecialty Board of Medical Oncology, and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988).
Presently, Dr. Spigelman serves on the Coordinating Board of the WHO Stop TB Partnership, is Co-Chair of the Working Group on New Drugs of the WHO Stop TB Partnership, and is a member of the Governing Board of the Tres Cantos Open Lab, GlaxoSmithKline.
Senior Director, CommunicationsJoanna Breitstein joined the TB Alliance in 2009. As Senior Director, Communications, she is responsible for charting and implementing the organization’s communications strategy and also serves as the primary contact for press inquiries.
Before joining the TB Alliance, Ms. Breitstein was the Executive Editor of Pharmaceutical Executive, a healthcare magazine focused on educating the executive leadership of the pharmaceutical industry. She worked for the publication for nearly a decade in roles of increasing responsibility, reporting on all aspects of drug development and commercialization. While at the magazine, Joanna pioneered an annual editorial series focused on neglected disease drug development, which garnered a Neal Award for excellence in business journalism in 2009. She also received a Neal Award for her cover story focusing on the convergence of diagnostics and pharmaceuticals and a Grand Neal Award in 2001 for a cover story on patient advocacy in oncology. In 2004, Ms. Breitstein won a writing fellowship from the Kaiser Family Foundation to report on the AIDS crisis in Africa.
Joanna is an active volunteer and serves as the President of The International HUG Foundation, a 501c3 organization whose mission is to help orphans and other needy children in Uganda. She graduated cum laude from Penn State University in 1995.
Senior Vice President, External AffairsWillo Brock joined TB Alliance in 2014. As the Senior Vice President of External Affairs he is responsible for providing strategic leadership to the TB Alliance's fundraising, advocacy and policy, and community and stakeholder engagement work. Prior to joining TB Alliance, Mr. Brock worked for large international development organizations like WWF and Habitat for Humanity. His passion is bringing together people, for profit organisations, governments and civil society to tackle global issues of insecurity and inequality and develop effective programs giving people opportunities for growth and development.
Mr. Brock started his career working for the Netherlands Ministry of Development in Pakistan and continued working for MDF Training & Consultancy gaining over ten years of management consultancy, training, coaching and project management experience focused on non-profit clients. He worked in over 90 countries globally.
Mr. Brock received his Masters in Business Administration from the Erasmus University in Rotterdam.
Daniel E. Everitt
Vice President and Senior Medical OfficerDr. Everitt serves as Senior Medical Officer and works with the clinical development of products in the TB Alliance portfolio. Prior to joining the TB Alliance, he spent 10 years in Johnson & Johnson’s pharmaceutical sector. There, Dr. Everitt served in various roles, including as Vice President and Global Head of Clinical Pharmacology and Experimental Medicine at Johnson & Johnson Pharmaceutical Research and Development, and as Vice President of Safety Governance. Before working at Johnson & Johnson, Dr. Everitt spent 10 years in clinical research and development at SmithKline Beecham Pharmaceuticals. For six years, he was an Investigator in the Clinical Pharmacology Research Unit based at the University of Pennsylvania, and subsequently led Phase 2-4 development projects based in Harlow, United Kingdom, in the areas of neurosciences and anti-infectives.
Dr. Everitt gained his undergraduate degree from Duke University and his medical degree from Harvard Medical School. After an Internal Medicine residency at the Massachusetts General Hospital, he was a Fellow at Harvard in Geriatric Medicine and Clinical Epidemiology. Dr. Everitt is Board Certified in Internal Medicine, Geriatric Medicine and Clinical Pharmacology. He served on the faculty of departments of medicine at Harvard Medical School and at the University of Pennsylvania. In 2011, Dr. Everitt completed training and received a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine. Just prior to joining the TB Alliance, Dr. Everitt spent several months as a volunteer physician working in mission hospitals in Kenya. He is an author or co-author of 50 publications in peer-reviewed journals in the fields of Clinical Pharmacology and Pharmacoepidemiology.
Chief Scientific OfficerAs Chief Scientific Officer for the TB Alliance, Dr. Nader Fotouhi guides and oversees the organization’s research and preclinical development activities.
Dr. Fotouhi has 24 years of experience in the pharmaceutical industry, with significant research and early development expertise in a variety of therapeutic areas. Prior to joining the TB Alliance, Dr. Fotouhi held various leadership positions at Hoffmann-La Roche, including the head of the Discovery Chemistry group at the Nutley New Jersey site, the global head of Discovery Technologies, and served as the Nutley New Jersey Pharma Research and Early Development Site Leader.
Dr. Fotouhi holds a Ph.D. and Post Doctoral fellowship in Organic Chemistry from the Massachusetts Institute of Technology. Dr. Fotouhi has authored or co-authored more than 50 articles and presentations and holds 20 patents.
Chief Financial OfficerStephen Jasko is the Chief Financial Officer for the TB Alliance, responsible for overseeing all financial activities. He brings to the organization more than 20 years of experience in financial planning and resource management, and has a history of building organizational excellence in biopharmaceutical and financial companies ranging from small entrepreneurial start-ups to $100B multinationals.
Prior to the TB Alliance, Steve spent six years at Celgene, a New Jersey-based biotechnology company. During his tenure, Steve served as Vice President of Finance and Business Development for the Cellular Therapeutics Division, where he had P&L responsibilities, engaged in M&A and licensing activities, and strategic planning. Prior to that position, he spent five years serving as Celgene’s Treasurer and helped guide the company through a growth period that resulted in a seven-fold increase in market capitalization. Previously, Mr. Jasko also served in positions of increasing responsibility at Merck, MetLife, and Merrill Lynch.
Steve is a member of his local Board of Education and has volunteered in support of many local children’s recreational activities. He has a Bachelors of Science degree in Computer Sciences from Montclair University and an MBA in Finance from Rutgers.
Robert C. Lorette
Senior Vice President, Business DevelopmentRobert C. Lorette, Esq. is Senior Vice President of Business Development for the TB Alliance. In this role,
Mr. Lorette helps lead the TB Alliance’s efforts to establish agreements and strategic alliances within the context of the product development partnership (PDP) business model, and thus play an integral role in achieving the portfolio development and related resource mobilization goals of the TB Alliance.
Before joining the TB Alliance, Mr. Lorette founded and was President and CEO of Boston Life Science Advisors, a corporate development consulting firm dedicated to serving biotech, medical device and other life science organizations. He also co-founded and served as Managing Director of Transform Ventures LLC, a firm that brings capital, executive leadership, and engineering and manufacturing resources together to rapidly advance medical device technologies to a significant value inflection point.
Before founding these two companies, Mr. Lorette served as Chief Business Officer and Senior Vice President of Dynogen Pharmaceuticals, Inc., a clinical-stage drug development company focusing on gastrointestinal and genitourinary disorders. Earlier in his career, Mr. Lorette served in various management, corporate development, and legal roles for organizations such as Boston Healthcare Associates, Inc., UroMed Corporation, and Bausch & Lomb Incorporated.
Mr. Lorette received his law degree from Syracuse University College of Law and is admitted to practice law in Massachusetts, Connecticut, and New York. Additional accreditations include a Masters in Public Administration from the Maxwell School of Syracuse University and a Bachelor’s degree in economics from the College of the Holy Cross. Mr. Lorette also attended the Program for Management Development at the Harvard Business School.
Elana Robertson M.Sc.
Senior Vice President, Market AccessElana Robertson, a South African, joined the TB Alliance in June 2014 in the role of Senior Vice President, Market Access. In this role she is responsible for increasing the access and adoption of new TB regimens in the high-burden TB countries.
Elana, has 22 years of experience in the Pharmaceutical Industry, where she has been responsible for the marketing and commercialization of vaccines and pharmaceuticals on a global, regional and country level.
Before joining the Pharmaceutical Industry Elana was a Lecturer in Physiology at the University of Witwatersrand and a Researcher at the University of Stellenbosch.
She holds a Masters Degree in Physiology from the University of Stellenbosch in South Africa.
Senior Vice President, Research and DevelopmentAs Senior Vice President, Research and Development for the TB Alliance, Dr. Carl Mendel guides and oversees the organization’s research and development activities.
Dr. Mendel has more than 15 years of experience in the pharmaceutical industry, with significant research and development expertise in a variety of therapeutic areas, especially in early- and late-stage clinical development. Prior to his position with the TB Alliance, Dr. Mendel most recently served as Chief Medical Officer at Synvista Therapeutics. Prior, Dr. Mendel served in roles of increasing responsibility at Merck and Co., Knoll Pharmaceuticals (a division of BASF Pharma), Aventis Pharmaceuticals, and Sanofi-Aventis. During his career, he has contributed to the successful approvals of numerous pharmaceutical products that have been launched around the world.
Dr. Mendel holds a B.A. degree from Columbia University and an M.D. degree from the University of California, San Diego. He is board certified in Internal Medicine and in Endocrinology and Metabolism. Before joining the pharmaceutical industry, he was Assistant Professor of Medicine at the University of California, San Francisco. Dr. Mendel has authored or co-authored more than 50 articles in leading scientific journals.
Chief Administrative OfficerColleen Pero is Chief Administrative Officer for the Global Alliance for TB Drug Development.
In this role, she ensures operating effectiveness and management for the organization, and has specific oversight for cross-cutting strategies such as the TB Alliance pediatric initiative. Ms. Pero also serves as management liaison to the Board of Directors and corporate secretary. Additionally, Ms. Pero oversees internal operations, contracts administration, human resources, and information technology, among other areas, and is a member of the Senior Management Team.
An accomplished health care executive, Ms. Pero has a diverse professional background that includes over twenty years in the healthcare sector in both for-profit and not-for-profit environments. Before joining the TB Alliance, Ms. Pero was Senior Vice President, Corporate Administration at $2B specialty pharmaceutical and healthcare company Endo, where she built organizational capabilities to enable rapid growth, and participated in six-fold expansion of the market capitalization over five years. As a member of the executive team, Ms. Pero contributed to the establishment and execution of corporate strategy for the business, and she had direct responsibility for a wide range of areas including organizational planning, information technology, communications, company affairs, procurement, human resources and organizational development.
Since 2005, Ms. Pero has served as a Trustee for Christiana Care Health System, a $1.5B integrated healthcare system. She serves on the Executive Compensation Committee, which is responsible for executive and physician compensation, leadership development, and succession planning. Ms. Pero holds an MA in Management and a Bachelor of Science degree.